RenovoRx: Efficacy/drug delivery potential of TAMP improve cancer therapy

RenovoRx announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion or TAMP therapy platform. The data was published online in the peer-reviewed Journal of Vascular Interventional Radiology, JVIR, journal and will also be published in the print version. The manuscript is authored by Khashayar Farsad, MD, PhD of the Department of Interventional Radiology at Oregon Health and Science University, and co-authored by Paula M. Novelli, MD, of the University of Pittsburgh Hillman Cancer Center, together with other researchers, including RenovoRx’s Chief Medical Officer, Dr. Ramtin Agah. …”TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,” said Dr. Farsad. “The study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes of the Phase III clinical trial, currently underway, to validate this benefit.” Dr. Farsad adds, “This platform has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery.”